Astellas promotes Percival Barretto-Ko

Moves from Europe to the US as vp of corporate strategy and government affairs

Astellas US, the American business of Tokyo-based pharmaceutical manufacturer Astellas Pharma, has named Percival Barretto-Ko as senior vice president, corporate strategy and government affairs, a new position added to the company's leadership team.

Reporting to president and ceo Masao Yoshida, Barretto-Ko will be responsible for corporate planning, business development, government policy and external affairs and state government affairs.

‘This realignment brings key strategic functions closer together at the corporate level,’ said Yoshida. ‘Percival has an outstanding track record both in the pharmaceutical industry and at Astellas' European operations. He will be a great addition to our senior management team.’

Barretto-Ko will move to the new role from executive director, corporate strategy and communications at Astellas Pharma Europe.

Prior to joining Astellas, he held senior marketing and sales positions at the Roche Group in the US and UK.

You may also like

Regulatory

Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma

The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Regulatory

Padcev plus Keytruda approved for advanced urothelial cancer by the EC

The therapeutic combination will now be named as the first-line, standard of care treatment for metastatic or advanced bladder cancer
Research & Development

Astellas Pharma doses first patient in Phase III trial for Fezolinetant

Fezolinetant aims to mitigate the impact of hot flushes, which are the most common side effect associated with endocrine therapy for breast cancer
Manufacturing

Astellas begins construction of manufacturing site in Tralee

600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Regulatory

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Manufacturing

Astella invests $3.5m in antibody drug facility

Drug producer Astella is set to submit a planning application to build a new facility in Tralee (County Kerry), Ireland, to expand its capacity to develop antibody drugs
Ingredients

Therapeutic: zolbetuximab for gastric cancer

Stomach cancer is the fifth most commonly diagnosed form of cancer, with risk factors including age, smoking, H. pylori infection and gastro-oesophageal reflux disease
Subscribe now